Low circulating microRNA levels in heart failure patients are associated with atherosclerotic disease and cardiovascular-related rehospitalizations by Vegter, Eline L. et al.
Vol:.(1234567890)
Clin Res Cardiol (2017) 106:598–609
DOI 10.1007/s00392-017-1096-z
1 3
ORIGINAL PAPER
Low circulating microRNA levels in heart failure patients are 
associated with atherosclerotic disease and cardiovascular-related 
rehospitalizations
Eline L. Vegter1 · Ekaterina S. Ovchinnikova1,2 · Dirk J. van Veldhuisen1 · 
Tiny Jaarsma3 · Eugene Berezikov2 · Peter van der Meer1 · Adriaan A. Voors1 
Received: 29 September 2016 / Accepted: 22 February 2017 / Published online: 14 March 2017 
© The Author(s) 2017. This article is published with open access at Springerlink.com
P < 0.05). Target prediction and network analyses identified 
several interactions between miRNA targets and biomark-
ers related to inflammation, angiogenesis and endothelial 
dysfunction. Lower miRNA levels were associated with 
higher levels of these atherosclerosis-related biomarkers. In 
addition, lower miRNA levels were significantly associated 
with rehospitalizations due to cardiovascular causes within 
18 months, with let-7i-5p as strongest predictor [HR 2.06 
(95% CI 1.29–3.28), C-index 0.70, P = 0.002].
Conclusions A consistent pattern of lower levels of cir-
culating miRNAs was found in heart failure patients with 
atherosclerotic disease, in particular peripheral arterial 
disease. In addition, lower levels of miRNAs were associ-
ated with higher levels of biomarkers involved in athero-
sclerosis and an increased risk of a cardiovascular-related 
rehospitalization.
Keywords Circulating microRNAs · Heart failure · 
Atherosclerosis · Biomarkers · Rehospitalization
Introduction
MicroRNAs (miRNAs) can function as important regula-
tors of a wide range of biological processes and contribute 
to the development of various diseases, including heart fail-
ure [1]. These small, non-coding RNAs are potent regula-
tors of gene expression, which function via binding to the 
target messenger RNA (mRNA). This in turn leads to either 
degradation of the mRNA or to repression of translation, 
resulting in a disturbed protein synthesis [2]. Extracellu-
lar miRNAs can be detected in circulating blood, and have 
shown to function as potential biological markers in heart 
failure [1, 3, 4]. A variety of studies identified differentially 
expressed circulating miRNAs in heart failure [5–7]. We 
Abstract 
Objective Circulating microRNAs (miRNAs) have been 
implicated in both heart failure and atherosclerotic disease. 
The aim of this study was to examine associations between 
heart failure specific circulating miRNAs, atherosclerotic 
disease and cardiovascular-related outcome in patients with 
heart failure.
Methods The levels of 11 heart failure-specific circulat-
ing miRNAs were compared in plasma of 114 heart fail-
ure patients with and without different manifestations of 
atherosclerotic disease. We then studied these miRNAs in 
relation to biomarkers associated to atherosclerosis and to 
cardiovascular-related rehospitalizations during 18 months 
of follow-up.
Results At least one manifestation of atherosclerotic dis-
ease was found in 70 (61%) of the heart failure patients. A 
consistent trend was found between an increasing number 
of manifestations of atherosclerosis (peripheral arterial 
disease in specific), and lower levels of miR-18a-5p, miR-
27a-3p, miR-199a-3p, miR-223-3p and miR-652-3p (all 
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recently reported about a panel of circulating miRNAs that 
consistently showed lower plasma levels in (acute) heart 
failure patients compared to healthy controls [7]. A gradual 
increase in miRNA levels was seen towards more stabilized 
heart failure patients, chronic heart failure patients and 
healthy controls.
Remarkably, no cardiac specific or cardiac-enriched 
miRNAs (such as miR-1, miR-133, miR-499 and miR-208) 
were present in this set of heart failure-related miRNAs, 
suggesting that the most differentially expressed miRNAs 
in the circulation of heart failure patients do not originate 
from the heart. Several studies showed that blood and 
endothelial cells are the major source of abundant miRNAs 
in the circulation [8, 9] and literature on our previously 
found miRNA signature in heart failure revealed potential 
involvement in vascular-related processes including angio-
genesis, endothelial dysfunction and inflammation [10–15]. 
Disturbances in these processes are frequently present in 
patients with atherosclerosis [16], therefore we hypothe-
sized that the previously found circulating miRNAs in heart 
failure might be related to atherosclerosis and underlying 
vascular disease processes.
To investigate this, we measured the previously estab-
lished heart failure-related miRNA panel in another cohort 
of 114 heart failure patients, consisting of patients with and 
without atherosclerotic disease. We aimed to identify dif-
ferences in circulating heart failure-related miRNA levels 
in heart failure patients with and without different clini-
cal manifestations of atherosclerosis, including coronary 
artery disease (CAD), a medical history of stroke or tran-
sient ischemic attack (TIA) and peripheral arterial dis-
ease (PAD). In addition, we studied associations between 
miRNA levels and biomarkers related to atherosclerotic 
disease processes such as inflammation, angiogenesis and 
endothelial dysfunction, and we assessed the relation with 
the risk of rehospitalization due to cardiovascular (CV)-
related causes.
Materials and methods
Study population
From the 1023 patients of the Coordinating Study Evaluat-
ing Outcomes of Advising and Counseling in Heart Fail-
ure (COACH), a subset of 114 randomly selected patients 
was studied based on the availability of plasma samples 
and complete biomarker measurements at baseline. The 
main results of the COACH study were previously pub-
lished [17]. Briefly, the COACH study investigated the 
effect of additional specialized nurse-led support with dif-
ferent intensities on outcome parameters in patients with 
heart failure. All patients had been admitted to the hospital 
with symptoms of heart failure, New York Heart Associa-
tion (NYHA) functional classification II to IV. Blood sam-
ples were collected shortly before discharge. Data on dis-
ease history was collected from the medical charts. Patients 
were divided according to the presence of 0, 1, 2 or 3 mani-
festations of atherosclerotic disease. The three manifesta-
tions of atherosclerotic disease consisted of CAD (defined 
as either a medical history of a myocardial infarction and/
or a revascularization procedure by means of percutane-
ous coronary intervention (PCI) or coronary artery bypass 
grafting (CABG) surgery), TIA or stroke (defined as a 
medical history of either a TIA and/or a stroke) and PAD 
(defined as a medical history of PAD). Healthy control sub-
jects (n = 10) were derived from the Telosophy study [18]. 
Main exclusion criteria of the control subjects were pres-
ence of heart failure, a family history of premature CV dis-
ease and known atherosclerotic disease.
MicroRNA measurements
RNA was isolated from plasma samples using the miR-
CURY RNA isolation kit for bodyfluids from Exiqon 
(Vedbaek, Denmark). The Universal cDNA Synthesis kit 
(Exiqon) was used for the reversed transcription reactions. 
The levels of the following previous identified circulat-
ing miRNAs [7] in heart failure patients were determined 
in plasma from 114 heart failure patients using a custom-
ized Exiqon miRNA PCR panel; let-7i-5p, miR-16-5p, 
miR-18a-5p, miR-26b-5p, miR-27a-3p, miR-30e-5p, miR-
106a-5p, miR-199a-3p, miR-223-3p, miR-423-5p and 
miR-652-3p. Circulating levels of these miRNAs were also 
measured in plasma samples from ten healthy control sub-
jects, as previously described [7]. Polymerase chain reac-
tions were performed on the  LightCycler® 480 (Roche 
Applied Science, Rotkreuz, Switzerland) with cycle set-
tings as recommended by Exiqon. Synthetic RNA tem-
plates were used to control for isolation yield (UniSp4), 
cDNA synthesis (UniSp6) and PCR efficiency (UniSp3). 
Only miRNAs with Ct values less than 37 were included in 
the further analyses. The miRNA let-7a-5p was selected as 
best performing reference gene in the investigated cohorts, 
as determined by GeNorm and NormFinder (GenEx Pro-
fessional software, MultiD Analyses, Sweden). Expression 
levels of the measured miRNAs were normalized against 
miRNA let-7a-5p using the GenEx Professional software 
and the delta Ct method was performed to obtain the rela-
tive miRNA expression levels (the Ct value of the refer-
ence miRNA was subtracted from the Ct value of the tar-
get miRNA). High miRNA expression is reflected by low 
delta Ct values (representing a low number of fractional 
cycles needed to reach the threshold of the amplified tar-
get miRNA), and low miRNA expression by high delta Ct 
values.
600 Clin Res Cardiol (2017) 106:598–609
1 3
Biomarker measurements
Plasma concentrations of the majority of atherosclerosis-
related biomarkers were measured by Alere™, San Diego, 
CA. Competitive ELISAs on a  Luminex® platform were 
used to measure the biomarkers angiogenin, C-reactive pro-
tein (CRP), D-dimer, endothelial cell-selective adhesion 
molecule (ESAM), growth differentiation factor 15 (GDF-
15), lymphotoxin beta receptor (LTBR), myeloperoxidase 
(MPO), neutrophil gelatinase-associated lipocalin (NGAL), 
neuropilin-1, osteopontin, pentraxin-3, polymeric immuno-
globulin receptor (PIGR), receptor for advanced glycation 
endproducts (RAGE), syndecan-1, tumor necrosis factor 
alpha receptor 1 (TNFR-1), tumor necrosis factor recep-
tor superfamily member (troy) and vascular endothelial 
growth receptor 1 (VEGFR-1). Endothelin-1 and interleu-
kin-6 (IL-6) were measured by means of the high sensi-
tive single molecule counting (SMC™) technology (RUO, 
 Erenna® Immunoassay System) by Singulex Inc. (Alameda, 
CA, USA). Galectin-3 was measured using the BG Medi-
cine galectin-3 assay (BG Medicine, Waltham, MA), more 
extensively described elsewhere [19]. The inter- and intra-
assay coefficients of variation for each of the biomarkers 
were previously published [20].
Target prediction and network analysis
Potential targets of the set of circulating miRNAs were pre-
dicted using miRTarBase 6.0 [21]. Only experimentally 
validated targets (by means of reporter assay, western blot, 
microarray or next-generation sequencing) were selected 
to increase the reliability of the identified targets. Next, an 
interaction network of the overlapping miRNA targets (i.e. 
genes targeted by more than one of the investigated miR-
NAs) was created using STRING v.10 [22].
Statistical analyses
GenEx Professional software (MultiD Analyses, Swe-
den) was used for the raw miRNA expression data. Other 
statistical analyses were conducted with R: A Language 
and Environment for Statistical Computing, version 3.2.0 
(R Foundation for Statistical Computing, Vienna, Aus-
tria). Normally distributed variables were depicted as 
mean ± standard deviation and non-normally distributed 
variables were presented as median with the interquar-
tile range. Differences between groups were determined 
using t tests for normally distributed continuous variables 
and Mann–Whitney U tests for non-normally distributed 
continuous variables. For binomially and categorical vari-
ables, the Chi-square test was used. Linear trend tests were 
used for miRNA and biomarker levels across groups and 
quartiles. To examine the predictive value of miRNAs for 
various endpoints uni- and multivariable Cox proportional 
hazards regression analyses were performed. P values of 
<0.05 were considered significant.
Results
Baseline characteristics of the study population
Baseline characteristics of the 114 hospitalized heart fail-
ure patients at time of discharge are presented in Supple-
mentary Table 1. Patient characteristics were similar to the 
complete COACH population, mostly male, with a mean 
age of 71.1 (±10.4) years and median NT-proBNP of 3566 
[1661–7848] pg/mL. Forty-four patients (39%) had no ath-
erosclerotic disease and 70 (61%) had at least one mani-
festation of atherosclerotic disease. From the 114 patients, 
54% showed evidence of CAD, 13% had a medical history 
of a previous stroke and/or TIA and 21% had PAD.
Circulating microRNA levels in patients with heart 
failure compared to controls
To confirm our previous findings of lower miRNA levels 
in heart failure patients compared to control subjects, we 
compared the circulating miRNA levels of the 114 patients 
to a control cohort consisting of ten healthy subjects. Base-
line characteristics of the control population are depicted 
in Supplementary Table 1. In concordance with our previ-
ous study [7], we found lower levels of the majority of the 
heart failure-related circulating miRNAs in heart failure 
patients compared to controls, with the exception of miR-
423-5p and miR-16-5p showing higher and unchanged 
levels, respectively (Supplementary Fig.  1). Statistically 
significant lower levels in heart failure patients compared 
to healthy individuals were found for miR-18a-5p, miR-
26b-5p, miR-27a-3p, miR-30e-5p, miR-199a-3p and miR-
223-3p (Table 1).
Associations of microRNA levels with the number 
of different manifestations of atherosclerosis
Next, we assessed the relation between the extensiveness of 
atherosclerotic disease in heart failure patients and circulat-
ing miRNA levels. Patients were divided based on the num-
ber of different manifestations of atherosclerosis, including 
the presence of CAD, PAD and a history of stroke/TIA. 
For the majority of the miRNAs, the same pattern could be 
observed in which miRNA levels decreased in parallel with 
an increase of different manifestations of atherosclerotic 
disease (Table 2). The gradual decline in plasma levels of 
miR-18a-5p, miR-27a-3p, miR-199a-3p, miR-223-3p and 
miR-652-3p were statistically significant.
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Differences in circulating microRNA levels in heart 
failure patients with coronary artery disease, a medical 
history of stroke or transient ischemic attack, 
and peripheral arterial disease
To examine the effects of different manifestations of athero-
sclerotic disease on miRNA levels in more detail, we deter-
mined the differences in miRNA levels between the heart 
failure patients with or without CAD, a medical history of 
TIA/stroke and PAD. Clinical characteristics of patients 
belonging to these different categories of atherosclerosis 
are depicted in Table  3. There were no consistent trends 
in plasma levels of the selected miRNAs in patients with 
and without CAD (Supplementary Table 2A) and patients 
with a previous stroke or TIA (Supplementary Table 2B). 
In heart failure patients with PAD, several miRNA differ-
ences were found compared to heart failure patients with-
out PAD. Plasma concentrations of all miRNAs (except for 
miR-423-5p) were lower in heart failure patients with PAD 
compared to heart failure patients without PAD (Table 4) 
and miR-18a-5p, miR-27a-3p, miR-30e-5p, miR-106a-5p, 
miR-199a-3p, miR-223-3p and miR-652-3p showed signifi-
cantly lower circulating miRNA levels. Notably, heart fail-
ure patients with PAD had lower diastolic blood pressure 
and more patients had CAD (Table  3). Further, patients 
with PAD more often developed renal impairment with 
higher creatinine and potassium levels and a lower esti-
mated glomerular filtration rate. The majority of the asso-
ciations between the differentially expressed miRNAs and 
the presence of PAD remained after adjustment for these 
variables.
Associations between circulating microRNAs 
and biomarkers
We performed target prediction analysis to identify the 
experimentally validated potential targets of the panel of 
heart failure-related miRNAs. We selected the overlap-
ping targets (i.e. mRNAs targeted by more than one of the 
investigated miRNAs) and show that the majority of these 
targets interact which each other, as presented in the net-
work figure (Supplementary Fig. 2). Genes with a central 
Table 1  Circulating microRNA levels in heart failure patients (HF) 
compared to control subjects
Values represent the normalized (delta Ct) miRNA levels presented 
as mean ± standard deviation or median with interquartile range (in 
square brackets)
Variable Controls HF P value
N 10 114
let-7i-5p 0.5 ± 0.5 0.8 ± 1 0.095
miR-16-5p −6.1 ± 1.1 −6 ± 1.3 0.819
miR-18a-5p 1.1 ± 0.6 2.5 ± 1.1 <0.001
miR-26b-5p 2.1 ± 0.6 3.7 ± 0.9 <0.001
miR-27a-3p −1.8 ± 0.6 −0.5 ± 1.1 <0.001
miR-30e-5p −0.6 ± 0.6 0 ± 1.2 0.028
miR-106a-5p −1.7 [−1.9 to 1.3] −0.6 ± 1 0.079
miR-199a-3p −0.6 ± 0.6 0.6 ± 1 <0.001
miR-223-3p −5.2 [−5.5 to 4.8] −4.5 ± 1.2 0.002
miR-423-5p 0.5 ± 1 −0.3 ± 1 0.028
miR-652-3p 0.8 ± 0.5 1.3 ± 1 0.060
Table 2  Circulating microRNA levels in patients with 0, 1, 2 or 3 different manifestations of atherosclerotic disease
Number of manifestations of atherosclerotic disease are presented, including coronary artery disease (CAD), peripheral arterial disease (PAD) 
and stroke/transient ischemic attack (TIA). Values represent the normalized (delta Ct) miRNA levels presented as mean ± standard deviation
Variable 0 1 2 3 P-for-trend
CAD n = 37 CAD n = 21 CAD n = 4
PAD n = 3 PAD n = 17 PAD n = 4
Stroke/TIA n = 3 Stroke/TIA n = 8 Stroke/TIA n = 4
N 44 43 23 4
let-7i-5p 0.9 ± 0.8 0.7 ± 1 0.8 ± 1.1 0.6 ± 1.1 0.549
miR-16-5p −6 ± 1.1 −6.1 ± 1.4 −6 ± 1.4 −5.9 ± 1.7 0.862
miR-18a-5p 2.3 ± 0.9 2.5 ± 1.3 2.8 ± 1.1 3.6 ± 1.5 0.020
miR-26b-5p 3.8 ± 0.9 3.6 ± 0.9 3.8 ± 1.1 3.9 ± 0.6 0.718
miR-27a-3p −0.7 ± 0.9 −0.5 ± 1.3 −0.5 ± 0.9 0.7 ± 1.7 0.014
miR-30e-5p 0 ± 1.2 −0.2 ± 1.2 0.2 ± 1.2 0.7 ± 1.8 0.178
miR-106a-5p −0.8 ± 0.9 −0.6 ± 1.1 −0.3 ± 1.1 0.1 ± 1.4 0.078
miR-199a-3p 0.5 ± 0.9 0.5 ± 1 0.7 ± 0.9 1.5 ± 1.3 0.038
miR-223-3p −4.8 ± 0.9 −4.4 ± 1.2 −4.1 ± 1.3 −3.5 ± 2.4 0.028
miR-423-5p −0.1 ± 0.7 −0.4 ± 1.2 −0.5 ± 0.9 −0.3 ± 1 0.730
miR-652-3p 1.2 ± 0.8 1.2 ± 1.1 1.6 ± 0.8 2.7 ± 1.5 0.002
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position in the network and multiple interactions with other 
target genes include FOXO1, MAPK14, CDK2, PTEN and 
SP1.
Biomarkers were selected based on known associa-
tions with atherosclerosis, inflammation, angiogenesis and 
endothelial dysfunction. We found a total of 201 interac-
tions between the set of biomarkers and all predicted 
miRNA targets (in total 213), resulting from the network 
analysis (Supplementary Table  3). MiRNAs differen-
tially expressed in heart failure patients with an increas-
ing number of manifestations of atherosclerosis and PAD 
were divided in quartiles based on their expression levels 
after which the trend with biomarker levels was determined 
(Table 5). A significant P-for-trend was observed for mul-
tiple biomarkers showing consistent trends of high levels 
in the patients with the lowest miRNA levels, including 
ESAM, LTBR, PIGR, pentraxin-3, troy, syndecan-1, galec-
tin-3, NGAL, GDF-15, RAGE, TNFR-1, neuropilin-1 and 
angiogenin. Low levels of miR-18a-5p, miR-106a-5p and 
miR-223-3p were significantly associated with high lev-
els of a variety of mainly inflammatory and endothelium-
related biomarkers (ESAM, LTBR, PIGR, syndecan-1, 
GDF-15, RAGE, TNFR-1, pentraxin-3, galectin-3, troy), 
whereas low levels of miR-27a-3p and miR-199a-3p were 
related to high levels of biomarkers important in angiogen-
esis-related processes (galectin-3, neuropilin-1 and angio-
genin), as summarized in Fig. 1.
Predictive value of circulating microRNAs 
and cardiovascular-related rehospitalization
We studied the association between our set of established 
circulating miRNAs and CV-related endpoints. Within 
18 months, 28 events of rehospitalization resulted from 
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Table 4  Circulating microRNA levels in heart failure patients with 
and without peripheral arterial disease (PAD)
Values represent the normalized (delta Ct) miRNA levels presented 
as mean ± standard deviation
Variable No PAD PAD P value
N 90 24
let-7i-5p 0.7 ± 0.9 1.1 ± 1 0.112
miR-16-5p −6.1 ± 1.2 −5.8 ± 1.4 0.248
miR-18a-5p 2.4 ± 1.1 3.1 ± 1 0.006
miR-26b-5p 3.7 ± 0.9 4 ± 0.9 0.118
miR-27a-3p −0.7 ± 1.1 −0.1 ± 1 0.018
miR-30e-5p −0.2 ± 1.2 0.7 ± 1.2 0.004
miR-106a-5p −0.7 ± 1 −0.1 ± 1 0.013
miR-199a-3p 0.4 ± 1 1 ± 0.9 0.010
miR-223-3p −4.6 ± 1.2 −3.8 ± 1.3 0.005
miR-423-5p −0.3 ± 1 −0.3 ± 0.9 0.986
miR-652-3p 1.1 ± 1 1.9 ± 0.8 <0.001
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Table 5  Circulating microRNAs significantly associated with atherosclerosis-related biomarkers
Biomarker values are presented in ng/mL per quartile of circulating miRNA levels, either as mean ± standard deviation or median with inter-
quartile range (in square brackets). Quartile 1 (Q1) represents the patients with the highest miRNA levels, whereas quartile 4 (Q4) represents the 
patients with the lowest miRNA levels
ESAM endothelial cell-selective adhesion molecule, GDF-15 growth differentiation factor 15, LTBR lymphotoxin beta receptor, NGAL neutro-
phil gelatinase-associated lipocalin, PIGR polymeric immunoglobulin receptor, RAGE receptor for advanced glycation endproducts, TNFR-1 
tumor necrosis factor alpha receptor 1, troy tumor necrosis factor receptor superfamily member, VEGFR-1 vascular endothelial growth receptor 1
miRNA quartiles Q1 Q2 Q3 Q4 P-for-trend
N 29 28 28 29
miR-18a-5p
 ESAM 56.5 ± 16.8 60.9 ± 14.6 64 ± 21.6 65.4 ± 16.7 0.048
 Galectin-3 20.4 ± 9.5 22.5 ± 8 25.3 ± 11 27.1 ± 10.4 0.007
 LTBR 0.7 [0.5–1] 0.8 [0.5–1.1] 0.8 [0.5–1.4] 0.9 [0.7–1.5] 0.017
 Pentraxin-3 3.8 ± 2.2 4.1 ± 1.6 4.8 ± 2.6 4.8 ± 2.3 0.045
 PIGR 695.3 [413.4–1081.1] 617.4 [512.4–998.1] 774.5 [439.7–1175] 831.6 [612.6–1194.2] 0.043
 RAGE 3 [2.1–5] 2.7 [1.8–4.3] 3.8 [2.7–6.1] 5 [3.7–6.3] 0.034
 Syndecan-1 19.7 [13.5–25.4] 20.8 [16.2–25.5] 24.9 [16.3–32.2] 22.4 [18.8–28.2] 0.030
 TNFR-1 3.1 [2.1–4.2] 3.4 [2.3–4.7] 3.3 [2.3–7.2] 4.6 [3–6.8] 0.037
 Troy 0.9 [0.8–1.5] 1 [0.9–1.6] 1.2 [0.7-2] 1.5 [0.9–2.2] 0.005
miR-30e-5p
 Galectin-3 21.5 ± 7.4 22.6 ± 9.7 25.2 ± 11.8 26.3 ± 10.4 0.043
miR-27a-3p
 Galectin-3 19.9 ± 7.5 23.5 ± 7.4 23.2 ± 10.4 29.1 ± 12 0.001
 Neuropilin-1 871.2 ± 234.6 953.1 ± 265.8 1007.6 ± 324.1 1091.5 ± 333.7 0.004
 NGAL 107.3 [84.3–161.3] 135.4 [101.1–169.9] 151.1 [103.4–178.2] 147.7 [112.8–229.3] 0.006
miR-106a-5p
 ESAM 55.9 ± 17.1 60.7 ± 17.1 57.4 ± 14.9 72.7 ± 16.9 0.001
 Galectin-3 20.6 ± 9.1 20.1 ± 5.8 24.9 ± 10.9 30.1 ± 10.3 <0.001
 GDF-15 2.7 [1.8–4.4] 3 [1.9–5.3] 3.3 [1.8–6.1] 4.1 [3.2–6.4] 0.012
 LTBR 0.6 [0.4–0.8] 0.8 [0.6–1.2] 0.8 [0.5–1.2] 1.2 [0.7–1.7] <0.001
 PIGR 559 [415.9–1029.5] 666.4 [421.4–1061.6] 689.6 [424.5–894.1] 1024.9 [778.2–1625.8] <0.001
 RAGE 3.1 [2.3–4.4] 3.4 [2.2–6] 3.4 [2.4–5.5] 5 [2.9–8.3] 0.011
 TNFR-1 2.6 [2.1–4.1] 3.1 [2.3–4.2] 3 [2.4–5.2] 5.1 [4.1–8.6] <0.001
 Troy 0.9 [0.8–1.6] 1 [0.8–1.4] 1.2 [0.6–1.7] 1.9 [1.2–2.6] <0.001
miR-199a-3p
 Angiogenin 3723.4 [2317.9–4907.5] 3819.8 [3252.4–5453.6] 4312.1 [2997.5–6143.4] 4595.5 [3104.5–6748.6] 0.024
 Galectin-3 21.7 ± 8.4 21.8 ± 8.8 24.8 ± 11.1 27.3 ± 10.7 0.018
 Neuropilin-1 871.8 ± 221.1 987 ± 330.6 1002.9 ± 260.9 1062.8 ± 350.3 0.018
miR-223-3p
 Galectin-3 19.8 ± 8.9 23.4 ± 9.3 24 ± 10.1 28.4 ± 10 0.001
 GDF-15 2.8 [1.8–4] 3.1 [1.9–5.4] 3.4 [1.8–6.1] 3.7 [2.6–6.1] 0.016
 LTBR 0.7 [0.5–1.1] 0.7 [0.5–1.3] 0.8 [0.5–1.3] 1 [0.7–1.6] 0.002
 PIGR 593.3 [440–1040.3] 738.8 [420.9–1092.3] 695.6 [408–904.3] 976.3 [659.6–1367.6] 0.004
 RAGE 3.1 [2.1–4.2] 3.6 [2.1–5.8] 3 [2.2–5] 5.7 [3.9–7.7] 0.006
 Syndecan-1 19 [16.6–24.7] 23.5 [15.1–28.3] 20.9 [16.2–30] 22.8 [20.3–34.2] 0.023
 TNFR-1 2.7 [2.1–3.7] 3.8 [2.3–5.3] 3.2 [2.6–5.3] 4.9 [3.2–7.5] 0.005
 Troy 1 [0.8–1.6] 1.2 [0.8–1.7] 1 [0.7–1.6] 1.5 [1–2.5] 0.001
 VEGFR-1 0.9 [0.1–1] 0.9 [0.6–1.2] 0.9 [0.6–1.2] 0.7 [0.5–1.7] 0.029
miR-652-3p
 RAGE 3 [2.3–4.5] 3.3 [2.1–5] 3.9 [2.1–6.2] 5 [3.1–7.5] 0.024
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CV causes (with exclusion of heart failure), of which 
18 (64%) were due to an atherosclerosis-related event 
(Supplementary Table  4). Univariable Cox proportional 
hazards analyses identified miR-106a-5p, miR-223-3p, 
miR-27a-3p, miR-16-5p, miR-30e-5p and let-7i-5p as 
significantly predictive for a CV-related rehospitalization 
(Fig. 2), showing consistent associations of low miRNA 
levels with an increased risk of reaching the endpoint. 
The addition of clinically relevant variables including 
age, sex, b-type natriuretic peptide (BNP) and estimated 
glomerular filtration rate (eGFR) resulted in 5 miRNAs 
remaining significantly predictive. C-statistics identi-
fied the model with let-7i-5p as best performing with a 
C-index of 0.70. The same analyses with these miRNAs 
miR-30e-5p miR-18a-5p miR-106a-5pmiR-199a-3p miR-223-3pmiR-27a-3p miR-652-3p
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Fig. 1  Overview of the biomarker profile corresponding to low 
circulating microRNA levels. The depicted miRNAs are all lower 
expressed in plasma of heart failure patients with PAD and multi-
ple manifestations of atherosclerotic disease. Low levels of these 
miRNAs are associated with high plasma levels of several biomark-
ers which are related to processes involved in atherosclerosis. ESAM 
endothelial cell-selective adhesion molecule, GDF-15 growth differ-
entiation factor 15, LTBR lymphotoxin beta receptor, NGAL neutro-
phil gelatinase-associated lipocalin, PIGR polymeric immunoglobulin 
receptor, RAGE receptor for advanced glycation end products, TNFR-
1 tumor necrosis factor alpha receptor 1 and troy; tumor necrosis fac-
tor receptor superfamily member
Fig. 2  Predictive value of circulating microRNAs for cardiovascular-
related rehospitalizations within 18 months. Univariable Cox propor-
tional hazards regression analyses were performed for all circulating 
miRNAs. Only univariable significant miRNAs (P < 0.05) were added 
to a clinical model including age, sex, eGFR and log(BNP). This 
clinical model reached a C-index of 0.611 (all variables P > 0.05). 
The hazard ratio (HR) is depicted with 95% confidence interval and 
should be interpreted per standard deviation. C-statistics were per-
formed to assess model performance (presented as C-index)
606 Clin Res Cardiol (2017) 106:598–609
1 3
and other clinical endpoints including heart failure rehos-
pitalization and mortality did not result in similar find-
ings. No significant associations were identified for 
any of the miRNAs with all-cause mortality within 18 
months and only miR-106a-5p was univariable predic-
tive for a heart failure rehospitalization and the primary 
combined endpoint (heart failure rehospitalization and/
or death within 18 months), as presented in Supple-
mentary Tables 5A-C. However, this association did not 
remain significant after adjustment for clinically relevant 
parameters.
Discussion
In the present study, we confirmed our previous finding 
of a specific set of miRNAs that were lower expressed in 
patients with heart failure compared with age-matched con-
trols. Within our group of heart failure patients, several of 
these heart failure-related miRNAs were lower in patients 
with multiple manifestations of atherosclerotic disease, 
and PAD in particular. These results were supported by the 
finding that low levels of these miRNAs were associated 
with high levels of several biochemical markers related to 
inflammation, angiogenesis and endothelial dysfunction, 
which are all involved in the development and progres-
sion of atherosclerosis. Finally, low levels of six of these 
heart failure specific miRNAs were shown to predict the 
risk of a CV-related readmission after a heart failure hos-
pitalization. These findings suggest a potential involvement 
of these miRNAs in atherosclerosis and related disease 
mechanisms.
Circulating microRNAs and peripheral arterial disease
Non-coronary atherosclerotic disease is a common comor-
bidity in heart failure patients and it has been shown to 
be an important predictor of the presence of CAD [23]. 
PAD in specific can be regarded to as generalized mani-
festation of atherosclerotic disease, which might explain 
why we found the most striking association between low 
levels of miRNAs and the presence of PAD. Few studies 
investigated the circulating miRNA profile in patients with 
PAD. Stather et  al. [24] identified several downregulated 
circulating miRNAs related to PAD with similarities to 
our investigated circulating miRNA panel, including miR-
16, miR-26b and miR-27b. Another study in patients with 
atherosclerotic abdominal aortic aneurysms found signifi-
cantly upregulated miR-223 levels in atherosclerotic tissue, 
whereas miR-223 levels in plasma were downregulated 
[25], in concordance with our study.
Associations between microRNAs 
and atherosclerosis-related disease mechanisms
The potential involvement of these miRNAs in athero-
sclerosis-related processes was further supported by the 
association between low levels of circulating miRNAs and 
elevated levels of biomarkers related to inflammation, angi-
ogenesis and endothelial dysfunction. Interestingly, these 
processes are all well-described disease mechanisms in 
both atherosclerosis [16, 26] and heart failure [27, 28].
Especially miR-18a-5p, miR-106a-5p and miR-223-3p 
were associated with a high number of mainly inflam-
matory and endothelium-related biomarkers, including 
ESAM, RAGE and pentraxin-3. Various roles for these bio-
markers have been described, including migration of neu-
trophils and macrophages [29], leukocyte adhesion [30], 
endothelial dysfunction and vascular homeostasis [31]. The 
associations between these biomarkers and several heart 
failure-related miRNAs coincide with previous associations 
of miR-18a-5p, miR-106a-5p and miR-223-3p with inflam-
mation and endothelial-related processes. In endothelial 
cells, miR-18a (part of the miR-17~92 cluster) was mainly 
described as anti-angiogenic [32], although a recent study 
reported that this cluster was required for endothelial cell 
proliferation and angiogenic sprouting after VEGF stimula-
tion [10]. This suggests that the miR-17~92 cluster exhibits 
complex roles in endothelial cell function and angiogen-
esis, although the precise understanding of the underlying 
mechanisms warrants further investigation. MiR-223 is a 
well-known inflammation-related miRNA and is abundant 
in platelets, leukocytes and endothelial-derived microvesi-
cles [11]. Besides its anti-angiogenic properties it was 
shown that miR-223 can function as potential contributor 
to the quiescence of endothelial cells [12]. Furthermore, 
MiR-106a has been associated to macrophage activation, 
suggesting involvement in inflammation [13].
We showed that low levels of miR-27a-3p and miR-
199a-3p were associated with angiogenesis-related markers 
including angiogenin, neuropilin-1 and galectin-3. MiR-27a 
is present in endothelial cells and was previously described 
as key regulator of endothelial cell sprouting and angiogen-
esis [14], suggesting a substantial involvement in vascular 
dysfunction. MiR-199a-3p is mainly described as hypoxia-
related miRNA and can function as promoter of metastasis 
and angiogenesis [15]. A potential role for miR-199a-3p in 
angiogenesis is also reflected in the present study by the 
observed association with angiogenesis-related markers.
Our target prediction and network analyses also imply 
involvement of the investigated miRNAs in atherosclero-
sis-related processes, since targets as FOXO1 and CDK2 
were previously shown to have key roles in the develop-
ment of atherosclerosis, including angiogenesis, oxidative 
stress and proliferation of smooth muscle cells [33, 34]. 
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Interestingly, both FOXO1 and MAPK14—another impor-
tant node in our network—were also implicated in the 
development of heart failure [35, 36], therefore the identi-
fied targets may reflect key regulating mechanisms in both 
atherosclerotic disease and heart failure.
Relation of circulating microRNAs to rehospitalization 
due to cardiovascular causes
Besides the associations with the clinical phenotype and 
biochemical profile of atherosclerosis, we found very con-
sistent associations between low levels of several miRNAs 
and CV-related rehospitalizations within 18 months, while 
no relations with other clinical endpoints including heart 
failure rehospitalization and mortality were found. Inter-
estingly, most of the CV readmissions were related to ath-
erosclerosis, suggesting that these miRNAs are able to pre-
dict the risk of atherosclerosis-related rehospitalizations in 
patients with heart failure.
Hospital readmission after a hospitalization for acute 
heart failure is a major problem and although biomarkers 
can predict response to acute heart failure treatment [37], 
few valuable predictors of long-term outcome besides the 
natriuretic peptides have been proposed so far [38]. Moreo-
ver, studies investigating the predictive value of circulat-
ing miRNAs in (acute) heart failure patients in relation to 
adverse outcome are scarce. Two studies identified miR-
423-5p as prognostic biomarker for a hospital readmis-
sion [39] and all-cause mortality [7] in acute heart failure 
patients, but in the current study this miRNA did not pre-
dict a CV-related rehospitalization. Here, we identified let-
7i-5p as strongest predictor of CV-related rehospitalizations 
and although there is no literature specifically addressing 
the relation of let-7i-5p with clinical outcome, the let-7 
family has been described before in relation to CV disease 
[40]. Not all miRNAs with significant predictive value for 
CV rehospitalization overlap with the miRNAs found to 
be related to the atherosclerotic phenotype and vice versa, 
which may indicate that some miRNAs mainly reflect 
processes underlying atherosclerosis while others have a 
stronger association with progressing disease and outcome 
parameters. Nevertheless, we found a highly consistent pat-
tern of lower miRNA levels associated with the atheroscle-
rotic disease phenotype as well as an increased risk of CV 
rehospitalizations.
Low circulating microRNA levels; increased uptake 
or decreased secretion?
The consistent pattern of decreased circulating miRNA lev-
els associated with different aspects of atherosclerotic dis-
ease is intriguing and leads to questions regarding their bio-
logical role in the circulation. One possible explanation for 
these low miRNA levels might lie in the increased uptake 
by recipient cells. It has been shown that circulating miR-
NAs can function in cell-to-cell communication and that 
recipient cells can engulf vesicle encapsulated miRNAs 
which consequently alters important cell functions [1]. In 
atherosclerosis, Zernecke et  al. demonstrated in  vitro that 
miR-126-enriched apoptotic bodies produced by endothe-
lial cells can be taken up by vascular cells to regulate VEGF 
[41]. On the other hand, a diminished release of miRNA-
enriched vesicles could also lead to downregulated miRNA 
levels in plasma. Since increased angiogenesis is associated 
with plaque progression and instability in atherosclero-
sis, it has been speculated that a reduced export of angio-
genic miRNAs outside cells might inhibit pro-angiogenic 
signaling [42]. Indeed, in serum of patients with CAD, it 
has been shown that extracellular vesicles are loaded with 
less CAD-related miRNAs in comparison to healthy sub-
jects [43]. However, the majority of the extracellular miR-
NAs are vesicle-free and bound to Ago proteins, of which 
no evidence of miRNA trafficking is currently available. 
Therefore, further research is needed to unravel the precise 
underlying mechanisms of reduced circulating miRNA lev-
els in patients with heart failure and atherosclerosis.
Study limitations
The limitations of this study should be acknowledged. First, 
although very consistent miRNA patterns were found, the 
studied patient population was relatively small. Second, 
the associations of heart failure-related circulating miR-
NAs with atherosclerosis and their role in common disease 
mechanisms such as vascular dysfunction should be further 
investigated in experimental settings to determine causal 
links.
Conclusions
Although the precise functions of circulating miRNAs 
in heart failure are still elusive, this study proposes a link 
between downregulated heart failure-related miRNAs and 
the presence of atherosclerosis and provides insight into 
potential related pathophysiological mechanisms including 
angiogenesis, inflammation and endothelial dysfunction. 
Further, we show the predictive value of these circulating 
miRNAs for the risk of a CV rehospitalization in heart fail-
ure patients. Future studies may elucidate the involvement 
of circulating miRNAs in heart failure and atherosclerosis-
related disease pathways, potentially leading to novel bio-
markers and drug targets.
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